Original Report

Symptoms, unmet need, and quality of life among recent breast cancer survivors


 

Background Assessing patient quality of life (QoL) apart from symptoms and unmet need may miss important concerns for which remediation is possible. Therapeutic advances have improved survival among breast cancer patients, and 89% can expect to survive for longer than 5 years. However, the price is lasting physical and psychosocial symptoms. Education regarding the value of symptom reduction may be needed for breast cancer survivors and their providers.

Objective To examine the unmet needs for symptom management and the relationships between unmet needs, symptom burden, and patient QoL.

Method Eligibility included nonmetastatic breast cancer survivors who had been treated less than a year before the study and attendance at a survivorship appointment. QoL was assessed using the Medical Outcomes Study Short Form-12 (scale, 0 [Did Not Experience] to 5 [As Bad As Possible]), and 19 symptoms were evaluated. Participants reported unmet need for assistance for each symptom experienced.

Results 164 primarily white, middle-aged, early-stage survivors of breast cancer were recruited. Physical and Mental QoL were similar to national norms. Survivors reported an average of 11.5 symptoms, most commonly Fatigue, Insomnia, Hot Flashes, Joint Pain, but reported unmet need for fewer symptoms (mean, 2.6). Weight Gain, Joint Pain, Numbness were most likely to result in unmet need. Both Physical and Mental QoL were negatively associated with number of symptoms (r = -.46 and -.41, respectively) and unmet needs (r = -.17 and -.41, respectively).

Limitations Cross-sectional sample of consecutive patients from a single clinical site.

Conclusion Symptoms are common among recent survivors of breast cancer, as are unmet needs, but to a lesser extent. Both have a negative impact on Physical and Mental health QoL.

Funding Translational Center of Excellence in Breast Cancer at the Abramson Cancer Center, University of Pennsylvania

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

In-person, telephone genetic counseling yield similar outcomes
MDedge Hematology and Oncology
FDA reports shortage of doxorubicin for injection, initiates importation
MDedge Hematology and Oncology
Point/Counterpoint: Should breast MRI be used routinely in the preoperative evaluation of breast cancer?
MDedge Hematology and Oncology
Long-term community-based results of breast-conserving therapy in early-stage breast cancer
MDedge Hematology and Oncology
Hereditary breast and ovarian cancer: risk assessment in minority women and provider knowledge gaps
MDedge Hematology and Oncology
Group-based psychosocial services: assessing outpatient oncology needs
MDedge Hematology and Oncology
I-SPY 2 graduates two neoadjuvant treatments to phase III trials
MDedge Hematology and Oncology
Ipsilateral arm BP measurements after breast cancer?
MDedge Hematology and Oncology
Safety of sentinel node dissection alone holds up a decade out
MDedge Hematology and Oncology
New data shed light on impact of resecting the primary tumor in stage IV breast cancer
MDedge Hematology and Oncology